Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Fusion Pharmaceuticals Inc. (FUSN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "FUSION PHARMACEUTICALS INC. CONDENSED CONSOLIDATED BALANCE SHEET DATA June 30, 2023 December 31, 2022 Cash, cash equivalents and investments $ 226,519 $ 186,635 Total assets 268,286 219,064 Total liabilities 65,325 56,843 Total stockholders' equity 202,961 162,221 FUSION PHARMACEUTICALS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Collaboration revenue $ 34 $ 570 $ 62 $ 1,155 Operating expenses: Research and development 18,994 12,076 34,871 24,737 General and administrative 7,753 7,781 16,759 16,230 Total operating expenses 26,747 19,857 51,630 40,967 Loss from operations Other income : Interest income 2,495 198 4,416 281 Interest expense Other income , net 80 64 Total other inco..."
05/11/2023 8-K Quarterly results
Docs: "Securities Purchase Agreement, by and among Fusion Pharmaceuticals Inc. and the Investors named therein",
"Registration Rights Agreement, by and among Fusion Pharmaceuticals Inc. and the Investors named therein",
"Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates"
03/16/2023 8-K Quarterly results
Docs: "FUSION PHARMACEUTICALS INC. CONDENSED CONSOLIDATED BALANCE SHEET DATA December 31, 2022 2021 Cash, cash equivalents and investments $ 186,635 $ 220,782 Total assets 219,064 252,271 Total liabilities 56,843 20,815 Total stockholders' equity 162,221 231,456 FUSION PHARMACEUTICALS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Collaboration revenue $ 140 $ 594 $ 1,461 $ 1,440 Operating expenses: Research and development 17,607 11,811 58,895 56,357 General and administrative 6,950 6,336 30,600 27,098 Total operating expenses 24,557 18,147 89,495 83,455 Loss from operations Other income: Interest income 1,309 81 2,161 381 Interest expense — — Other income, net 63 469 Total other income, ..."
11/08/2022 8-K Quarterly results
Docs: "FUSION PHARMACEUTICALS INC. CONDENSED CONSOLIDATED BALANCE SHEET DATA September 30, 2022 December 31, 2021 Cash, cash equivalents and investments $ 205,481 $ 220,782 Total assets 238,493 252,271 Total liabilities 55,351 20,815 Total stockholders' equity 183,142 231,456 FUSION PHARMACEUTICALS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Collaboration revenue $ 166 $ 325 $ 1,321 $ 846 Operating expenses: Research and development 16,551 12,684 41,288 44,546 General and administrative 7,420 7,156 23,650 20,762 Total operating expenses 23,971 19,840 64,938 65,308 Loss from operations Other income: Interest income, net 190 107 220 300 Other income, net 27 406 Total other income..."
08/09/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/17/2022 8-K Quarterly results
Docs: "Fusion Pharmaceuticals Announces Fourth Quarter 2021 Financial Results and Clinical Program Updates"
11/09/2021 8-K Quarterly results
Docs: "Fusion Pharmaceuticals Announces Third Quarter 2021 Financial Results and Clinical Program Update"
08/10/2021 8-K Quarterly results
Docs: "Fusion Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Update"
05/11/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "Fusion Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update"
08/11/2020 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy